A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

NCT00484289 ·Status: COMPLETED ·Phase: PHASE3

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480 ·Status: COMPLETED ·Phase: PHASE3

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

NCT01333878 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)

NCT01088321 ·Status: COMPLETED

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

NCT00162201 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

NCT04740814 ·Status: COMPLETED ·Phase: PHASE1

Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients

NCT01001832 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521 ·Status: COMPLETED ·Phase: PHASE3

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

NCT00837434 ·Status: COMPLETED ·Phase: PHASE4

Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia

NCT03663829 ·Status: COMPLETED

Phase IIIB Subcutaneous Missed Dose Study

NCT00533897 ·Status: COMPLETED ·Phase: PHASE3

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

NCT01481493 ·Status: COMPLETED ·Phase: PHASE2

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343 ·Status: COMPLETED ·Phase: PHASE3

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

NCT03227419 ·Status: UNKNOWN ·Phase: PHASE4

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

NCT00279734 ·Status: COMPLETED ·Phase: PHASE1

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

NCT01890473 ·Status: COMPLETED ·Phase: PHASE1

Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)

NCT00396812 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382 ·Status: COMPLETED ·Phase: PHASE3

Purify Antigen-specific B Cells From Patients With Rheumatoid Arthritis

NCT05203952 ·Status: UNKNOWN

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT00409838 ·Status: COMPLETED ·Phase: PHASE3

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

NCT02066389 ·Status: COMPLETED ·Phase: PHASE2